An observational study in Malignant Solid Tumors, Primary Brain Tumor and Melanoma, sponsored by N.N. Petrov National Medical Research Center of Oncology. Recruiting at 1 site in Russian Federation. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2024-05-06.
Sponsored by N.N. Petrov National Medical Research Center of Oncology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Brain Neoplasms with a site in Russian Federation — 1 open to participants now, 1 under way, none of them phase 3. Brain Neoplasms · Russian Federation.
Among the 13 studies in Brain Neoplasms with a site in Russian Federation, this one is the only one that started in 1998, is the only observational one, and was the 13th registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →1 of the 13 studies in Brain Neoplasms with a site in Russian Federation is open now.
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 7
First in 1998; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 99 across 433 observational studies indexed under Brain Neoplasms.
Median enrollment 138 across the 12 interventional studies, 1,000 across the 1 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 13 have an industry lead sponsor. The 7 most frequent:
N.N. Petrov National Medical Research Center of Oncology is the lead sponsor of 27 studies on the registry; 15 are open to participants now.
N.N. Petrov National Medical Research Center of Oncology has 1 study filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Brain Neoplasms with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies
The study will include patients with solid tumours receiving systemic therapy for their disease who do not have other significant factors that affect the immune system
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Progression in 3 mo
Presence of disease progression within 3 mo from sample aquisition
Time frame: 3 month
Overall survival (OS)
Time from sample aquisition to death from any reason
Time frame: Up to 5 years
Progression free survival
Time from sample aquisition to progression or death from the disease
Time frame: Up to 5 years
Response rate
Response assesmenr with RECIST 1.1 and iRECIST
Time frame: During the intervention
Plan to share: Undecided — Upon completion, the database is planned to be published with depersonalized data for cohorts with meaningful data. Cohorts to be published will be defined upon data check. Partial publications could be applicable.
Started Sep 1998 (actual). Primary completion is estimated for Dec 2030, 387 months after the start.
Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 387 months is above that.
Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
N.N. Petrov National Medical Research Center of Oncology